Tracking how well cancer immunotherapy is working using DNA from blood samples
Official title: Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA
Funded at Binary Genomics, INC. · NIH-10922080 · Data updated 2026-11-12
This study is looking at how we can better track how well immunotherapy is working for people with non-small cell lung cancer by checking for changes in cancer DNA found in their blood, which could help doctors make more personalized treatment choices.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Binary Genomics, INC. NIH-funded |
| Lab location | 1 site (Phoenix, UNITED STATES) |
| Project start | September 17, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $990,771 |
| NIH project number | 2R44CA285041-02 |
| Project ID | NIH-10922080 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are undergoing immunotherapy treatment.
✕Less likely to help
Patients with cancers that do not involve circulating tumor DNA or those not receiving immunotherapy may not benefit from this research.
What this research studies
This research focuses on improving the monitoring of immunotherapy responses in patients with non-small cell lung cancer by analyzing circulating tumor DNA (ctDNA) from blood samples. The approach utilizes a novel assay that detects epigenetic changes in cancer cell genomes, which can provide insights into treatment efficacy without the need for complex and costly tumor profiling. By identifying early changes in ctDNA levels, the research aims to better predict which patients will benefit from immunotherapy, potentially leading to more personalized treatment decisions.
Why it matters
Potential benefit: If successful, this research could lead to more accurate monitoring of immunotherapy responses, helping to identify effective treatments for patients with non-small cell lung cancer.
How similar studies have gone: Previous studies have shown promise in using ctDNA as a biomarker for monitoring cancer treatment, indicating that this approach has potential for success.
Where this research is happening
-
Binary Genomics, INC.
Phoenix, United States Active
Researchers
- Principal investigator: Barrett, Michael T — Binary Genomics, INC.
- Study coordinator: Barrett, Michael T
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.